title: The timing of granulocyte-colony-stimulating factor administration after chemotherapy does not affect stem and progenitor cell apheresis yield: a retrospective study of 65 cases.
abstract: BACKGROUND
  The optimal time for postchemotherapy granulocyte-colony stimulating factor (G-CSF) administration before peripheral blood stem and progenitor cell (PBPC) collection is not well defined. The impact of G-CSF scheduling on the number of CD34+ cells collected by leukapheresis from 65 patients with malignant disease was studied retrospectively.
  
  
  METHODS
  Chemotherapy was performed on Days 1 and 2 and was followed by G-CSF to mobilize PBPCs. In Group 1, 30 patients received the first dose of G-CSF immediately after the end of chemotherapy, as commonly recommended. In Group 2, 35 patients received the first G-CSF dose after the end of chemotherapy (Days 7 or 8).
  
  
  RESULTS
  No difference was observed between the two groups in white cell recovery and the median number of CD34+ cells harvested. The number of leukapheresis procedures necessary to obtain the minimal number of 3 x 10(6) CD34+ cells per kg was the same. The proportion of patients with a failure of PBPC collection was similar, and G-CSF consumption was reduced in Group 2 without increasing infectious risks.
  
  
  CONCLUSIONS
  Early administration of G-CSF after chemotherapy appears not to be a prerequisite for satisfactory PBPC collection. This approach could allow significant savings in terms of medical cost. A randomized and prospective study would be necessary, however, to assess the validity of these conclusions.
authors.affiliation: Department of Hematology and the Blood Center, Necker Hospital, Paris, France. bruno.varet@nck.ap-hop-paris.fr
authors.forename: F
authors.initials: F
authors.lastname: Lefrère
authors.forename: F
authors.initials: F
authors.lastname: Audat
authors.forename: O
authors.initials: O
authors.lastname: Hermine
authors.forename: M
authors.initials: M
authors.lastname: Cavazzana-Calvo
authors.forename: C
authors.initials: C
authors.lastname: Belanger
authors.forename: B
authors.initials: B
authors.lastname: Arnulf
authors.forename: A
authors.initials: A
authors.lastname: Buzyn
authors.forename: B
authors.initials: B
authors.lastname: Varet
mesh_terms: D000328:Adult; D000368:Aged; D001781:Blood Component Removal; D004358:Drug Therapy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019337:Hematologic Neoplasms / Q000188:drug therapy; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013234:Stem Cells / Q000166:cytology*; D013997:Time Factors
chemical_list: D016179:Granulocyte Colony-Stimulating Factor